Form 4 for SGMT Sagimet Biosciences Inc.
Accepted 2026-08-17 16:05:03 ET · period of report 2026-08-14 · accession 0001193125-26-354018 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-08-17 16:05 | 2026-08-14 | SGMT | Kemble George | Dir | M - OptEx | $6.36 | +351.0K | 413.1K | +565% | +$2.23M |
| DT | 2026-08-17 16:05 | 2026-08-14 | SGMT | Kemble George | Dir | S - Sale+OE | $10.23 | -351.0K | 62.2K | -85% | -$3.59M |
| DMT | 2026-08-17 16:05 | 2026-08-14 | SGMT | Kemble George | Dir | M - OptEx | $0.00 | -351.0K | 11.6K | -97% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Series A Common Stock | 2026-08-14 | M | A | 326,618 | $6.36 | 388,779 | D | — | — | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. |
| 2 | Common | Series A Common Stock | 2026-08-14 | M | A | 24,369 | $6.36 | 413,148 | D | — | — | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. |
| 3 | Common | Series A Common Stock | 2026-08-14 | S | D | 350,987 | $10.23 | 62,161 | D | — | — | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $10.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-08-14 | M | D | 326,618 | $0.00 | 31,455 | D | $6.36 · — to 2029-04-27 | 326,618 Series A Common Stock | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. (F3) This option is fully vested and exercisable as of the date hereof. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-08-14 | M | D | 24,369 | $0.00 | 11,608 | D | $6.36 · — to 2029-04-27 | 24,369 Series A Common Stock | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. (F3) This option is fully vested and exercisable as of the date hereof. |